Fenofibrate Tablets

  • Hyperlipoproteinemias

Fenofibrate Tablets Generic Name & Formulations

General Description

Fenofibrate 54mg, 160mg.

Pharmacological Class


How Supplied

Contact supplier

Fenofibrate Tablets Indications


Adjunct to diet: in severe hypertriglyceridemia; and to reduce elevated total-C, LDL-C, ApoB, and TG, and to increase HDL-C in primary hyperlipidemia and mixed dyslipidemia.

Fenofibrate Tablets Dosage and Administration


Take with food. Hypertriglyceridemia: 54mg–160mg/day; adjust in 4–8 week intervals. Hypercholesterolemia, dyslipidemia: 160mg/day. Renal impairment (CrCl<50mL/min): initially 54mg/day. Discontinue if inadequate response after 2 months on max dose.


Not established.

Fenofibrate Tablets Contraindications


Severe renal impairment. Dialysis. Active liver disease. Primary biliary cirrhosis. Unexplained persistent liver dysfunction. Gallbladder disease. Nursing mothers.

Fenofibrate Tablets Boxed Warnings

Not Applicable

Fenofibrate Tablets Warnings/Precautions


Renal impairment. Monitor CBCs for first year; monitor liver function, discontinue if ALT (SGPT) levels >3xULN persist. Discontinue if markedly elevated CPK levels, myopathy, or gallstones occur. Pregnancy.

Fenofibrate Tablets Pharmacokinetics

See Literature

Fenofibrate Tablets Interactions


Avoid statins. Potentiates oral anticoagulants (monitor). Allow at least 1 hour before or 4–6 hours after bile acid sequestrants. Caution with immunosuppressants (eg, cyclosporine), other nephrotoxic drugs.

Fenofibrate Tablets Adverse Reactions

Adverse Reactions

Abnormal liver function tests, elevated CPK, respiratory or GI effects, myopathy, cholelithiasis, pancreatitis, increased creatinine, rash; rare: rhabdomyolysis, transient hematologic changes, blood dyscrasias.

Fenofibrate Tablets Clinical Trials

See Literature

Fenofibrate Tablets Note


Formerly known under the brand name Lofibra.

Fenofibrate Tablets Patient Counseling

See Literature